

## Supplemental Digital Content 1: Studies Included

Protocol	Location	Title
004	Canada	Randomized, open-label, multi-center Phase IIB trial in Canada that assessed the immunogenicity and safety of DTaP5-HB-IPV-Hib VACCINE , administered concomitantly with Prevnar, in infants at <b>2, 4, 6 (primary series) and 15 months (4th Dose)</b> of age (NCT00362427)
005	US	A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at <b>2, 4, and 6 Months</b> Concomitantly with Prevnar 13™ and RotaTeq™ (NCT01337167)
006	US	A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at <b>2, 4, and 6 Months</b> Concomitantly with Prevnar 13™ and RotaTeq™ (NCT01340937)
007	Germany, Belgium, Finland	A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at <b>2, 3, 4, and 12 Months</b> (NCT01341639)
008	Italy, Sweden, Finland	A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at <b>2, 4, and 11 to 12 Months</b> (NCT01480258)
PRI01C	UK	Open-label, multicenter, randomized, Phase III study to evaluate the safety and immunogenicity of the concomitant administration of DTaP5-HB-IPV-Hib vaccine ( <b>2, 3, 4 Months</b> ) with two types of meningococcal serogroup C conjugate (MCC) vaccines (NCT01553279)